Skip to content
OpenCapital
Get started

Spero Therapeutics, Inc. SPRO Q4 2024 Annual earnings

Reported March 27, 2025 · After market close

Revenue$9.4MBeat by $3.2M
EPS-$0.38Miss by $0.03
Revenue estimate$6.2M
EPS estimate-$0.35

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$281.9K
EPS estimate-$0.17

Versus estimates

Revenue

Q1 2026$258.0KIn lineQ4 2025$41.3MBeat by $15.3MQ3 2025$3.0MMiss by $9.0MQ2 2025$11.8MBeat by $802.0KQ1 2025$5.9MMiss by $5.1M
Q4 2024$9.4MBeat by $3.2M

Diluted EPS

Q1 2026-$0.13Beat by $0.05Q4 2025$0.53Beat by $0.73Q3 2025-$0.13Beat by $0.12Q2 2025-$0.03Beat by $0.35Q1 2025-$0.25Beat by $0.30
Q4 2024-$0.38Miss by $0.03

Ask the moment Spero Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Spero Therapeutics, Inc. report Q4 2024 earnings?
Spero Therapeutics, Inc. (SPRO) reported Q4 2024 earnings on March 27, 2025 after market close.
What were Spero Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Spero Therapeutics, Inc. reported revenue of $9.4M and eps of $-0.38 for Q4 2024.
Did Spero Therapeutics, Inc. beat estimates in Q4 2024?
Revenue beat the consensus estimate of $6.2M by $3.2M. EPS missed the consensus estimate of $-0.35 by $0.03.
Where can I find Spero Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-046125) directly on SEC EDGAR. The filing index links above go to sec.gov.